A 52-Week Multi -Center Double-Blind Randomized Phase 2 Study Of Seladelpar, A Potent And Selective Peroxisome Proliferator-Activated Receptor Delta (Ppar-Delta) Agonist, In Patients With Nonalcoholic Steatohepatitis (Nash)
HEPATOLOGY（2020）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined